Home › Companies › LXEO

Lexeo Therapeutics

Market cap $236M 82.8M shares (10-Q, Nov 12, 2026) × $2.85 close Nov 17, 2026

Most recent annual filing: 2026-03-30

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. LX3010 / LX3030 LX3050 LX3070Early 2027LX3010 / LX3030 LX3050 LX3070, Early 2027, notable
  2. Next FA development candidate IND2027Next FA development candidate IND, 2027, notable
  3. LX2006 FA pivotal topline2H 2027LX2006 FA pivotal topline, 2H 2027, thesis-defining

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (12 active programs)

Technology platforms

Sf9-baculovirus AAV manufacturing platform

Optimized Sf9 baculovirus suspension-based AAV manufacturing process offering improved scalability and reduced cost while maintaining purity and potency, supporting cardiac genetic medicine programs.

Sf9 baculovirus manufacturing platform

Optimized Sf9 baculovirus AAV manufacturing platform designed for high yield, improved genomic purity, reduced empty capsids, and commercial-scale gene therapy production; supports Lexeo's cardiac and neurological gene therapy pipeline including LX2006 and LX2020.

Capital (as filed)

Cash
$90.2M cash and cash equivalents · Sep 30, 2026 (10-Q)
Short-term investments
$105M Sep 30, 2026
Long-term investments
$24.4M Sep 30, 2026
Operating cash flow
−$28.6M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$219M cash, runway into 2028 per the update of Nov 16, 2026 — the company's own words as read there, not the filed figure

Offering documents (1)

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.

Biotech Distilled coverage (7)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (7 calls)

Every verdict Biotech Distilled has published on Lexeo Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. Watch Lexeo Therapeutics (LXEO): Scientific Due Diligence for Lead and Pipeline Products Regulatory tailwinds (FDA acceptance of manufacturing switch and surrogate endpoint) and 3-year cash runway offer favorable risk/reward, but the author is waiting for the LX2020 safety dataset and pivotal protocol before committing capital.
  2. Buy speculative UPDATE: Lexeo (LXEO) Drops 25%+ on "Positive" Data – Why Did the Market Halt on the LX2020 Readout? Market overreacted to ambiguous efficacy language while ignoring definitive protein expression; the scientific thesis remains intact and the J&J collaboration provides a Plan B.
  3. Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The Pivotal Protocol Lands, and the FDA Just Dropped the Hardest Endpoint Three of four binary regulatory questions closed favorably (frataxin co-primary dropped, randomized design accepted, Sf9 commercial process cleared), and the pivotal trial is statistically powered against an effect size the drug has already exceeded in Phase I/II.
  4. Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The FDA Just Graded the Data the Market Failed RMAT designation confirms the FDA read the January interim LX2020 data as preliminary evidence of clinical benefit, giving LX2020 a plausible accelerated-approval path that didn't visibly exist before, while LX2006 remains the value driver.
  5. Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The Quiet ATM Operational execution matched the plan (first patient dosed, RMAT collected, G&A cut), but the ATM sold ~10% of the float at depressed prices, making the thesis slightly more expensive per share while leaving the core thesis intact.
  6. Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The $8.3 Million Pipeline and the Market's Shrug The Mantle acquisition costs roughly six weeks of burn and adds CNS FA optionality without touching runway or SUNRISE-FA 2 priority, but the 'focused cardiovascular specialist' framing no longer holds and the ATM overhang persists.
  7. Speculative buy speculative UPDATE: Lexeo Therapeutics (LXEO) - The Call Option Got Exercised 12-month high-dose HEROIC-PKP2 data show an 80% NSVT reduction running opposite to natural history, with FDA openness to NSVT as a pivotal surrogate, upgrading LX2020 from a call option to a second real pivotal asset alongside LX2006.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (31)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from May 11, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

20 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)